

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 57683

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China

Cost-effectiveness of infliximab maintenance therapy for CD

Abstract

BACKGROUND

Infliximab was the first approved biologic treatment for moderate to severe Crohn's disease (MS-CD) in China. However, the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD relative to conventional maintenance therapy remained unclarified.

AIM

To assess the cost-effectiveness of IMT for MS-CD in Chinese patients from the perspective of Chinese public insurance payer.

METHODS

A cohort of MS-CD patients managed in a Chinese tertiary care hospital was created to

Match Overview

1

Crossref 33 words

Haotian Chen, Jihao Shi, Yipeng Pan, Zhou Zhang, Hao Fan g, Ying Chen, Wendong Chen, Qian Cao. "Cost-Effectivene: ...

1%



ALL

IMAGES

VIDEOS

22,000 Results

Any time ▼

Comparison of Real-World Treatment Outcomes With ...

<https://academic.oup.com/crohnscolitis360/article/1/2/otz022/5545355> ▼

Aug 09, 2019 · INTRODUCTION. The incidence of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn **disease** (CD), peaks at about 20–29 years of age and may be rising in the US. 1 The total economic burden of IBD is substantial, with national estimates ranging between \$14.6 and \$31.6 billion. 2–6 With the growing number of biologics approved for IBD ...

Cited by: 1

Author: Haridarshan Patel, Dominick Latremouill...

Publish Year: 2019

Cost-Effectiveness of Reimbursing Infliximab for Moderate ...

<https://link.springer.com/article/10.1007/s12325-019-01150-x> ▼

Dec 03, 2019 · To assess the **cost-effectiveness** of reimbursing **infliximab for moderate-to-severe Crohn's disease** (MS-CD) in China from the perspective of public insurance payers. A decision-analytic model with a lifetime time horizon was constructed to simulate the **disease** progression and **direct medical costs** in Chinese MS-CD patients under two scenarios: reimbursing **infliximab** vs. not reimbursing **infliximab**.

Author: Haotian Chen, Jihao Shi, Yipeng Pan...

Publish Year: 2020

Evaluating the clinical and economic consequences of using ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697647>

Background. **Crohn's disease** (CD) is a chronic inflammatory bowel **disease** which induces ulcers, strictures, fistulas, and abscesses within the gastrointestinal tract.1 Every year in the US, about 11 new CD cases per 100,000 person-years are diagnosed;2 with estimates putting the US prevalence of CD at 780,000 patients or about 246.7 cases per 100,000 persons.2,3 The economic burden ...

Cited by: 1

Author: Rhodri Saunders, Rafael Torrejon Torres...

Publish Year: 2019

Reimbursing infliximab for Crohn's disease is cost ...

<https://www.normin.ca/post/reimbursing-infliximab-for-crohn-s-disease-is-cost>



国内版

国际版

Real-world cost-effectiveness associated with infliximab maintenanc



ALL

IMAGES

VIDEOS

23,500 Results

Any time ▼

Cost-Effectiveness of Reimbursing Infliximab for Moderate ...

<https://link.springer.com/article/10.1007/s12325-019-01150-x> ▼

Dec 03, 2019 · To assess the cost-effectiveness of reimbursing infliximab for **moderate-to-severe Crohn's disease (MS-CD) in China from the perspective of public insurance payers**. A decision-analytic model with a lifetime time horizon was constructed to simulate the disease progression and direct medical costs in Chinese MS-CD patients under two scenarios: reimbursing infliximab vs. not ...

Author: Haotian Chen, Jihao Shi, Yipeng Pan, Z...

Publish Year: 2020

Real-world cost–effectiveness of infliximab for moderate ...

<https://www.researchgate.net/publication/311778839...>

Real-world cost–effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of **China** Article in Journal of Comparative Effectiveness Research 6(3) · December ...

Cost-effectiveness of adalimumab, infliximab or ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860720>

May 03, 2016 · Infliximab 10 mg/kg every 8 weeks achieved a cost-effectiveness of **\$123 653 per MH achieved**, but an additional \$1.24 million is required to achieve one additional patient achieving MH after 1 year of treatment.

Cited by: 25

Author: Lauren Yokomizo, Berkeley Limketkai, K T ...

Publish Year: 2016

Health-economic analysis: Cost-effectiveness of scheduled ...

<https://www.researchgate.net/publication/5441249...>

Infliximab has been shown to be efficacious in **moderate-to-severe Crohn's disease (CD)**. To evaluate the



Real-world cost-effectiveness associated with infliximab maintenanc



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

47,500 Results

Any time ▾

[Cost-Effectiveness of Reimbursing Infliximab for Moderate ...](#)

<https://link.springer.com/10.1007/s12325-019-01150-x> ▾

To assess the cost-effectiveness of reimbursing infliximab for **moderate-to-severe Crohn's disease (MS-CD) in China from the perspective of public insurance payers**. A decision-analytic model with a lifetime time horizon was constructed to simulate the disease progression and direct medical costs in Chinese MS-CD patients under two scenarios: reimbursing infliximab vs. not reimbursing infliximab.

Author: Haotian Chen, Jihao Shi, Yipeng Pan,... **Publish Year:** 2020

[Real-world cost-effectiveness of infliximab for moderate ...](#)

<https://www.researchgate.net/publication/311778839...>

Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of **China** Article in Journal of Comparative Effectiveness Research 6(3) · December ...

[Health-economic analysis: Cost-effectiveness of scheduled ...](#)

https://www.researchgate.net/publication/5441249_Health-economic_analysis_Cost...

Infliximab has been shown to be efficacious in **moderate-to-severe Crohn's disease (CD)**. To evaluate the **cost-effectiveness** of scheduled **maintenance treatment with infliximab** in luminal and ...

[Cost-effectiveness of Biological Therapy Cycles in the ...](#)

<https://academic.oup.com/ecco-jcc/article/13/10/1323/5412099> ▾

Mar 20, 2019 · To examine the **cost-effectiveness** of continued **treatment** for patients with **moderate-severe Crohn's disease** in clinical remission, with a combination of anti-tumour necrosis factor alpha [anti-TNFα] [**infliximab**] and immunomodulator **therapy** compared with two different withdrawal strategies: [1] withdrawal of the anti-TNFα **therapy**; and [2 ...

Cited by: 2 **Author:** Kristian Bolin, Erik Hertervig, Edouard Louis

Publish Year: 2019

[Cost-Utility Analysis of Biologic Treatments for Moderate ...](#)

<https://www.researchgate.net/publication/224824687...>

Jun 01, 2012 - Adalimumab was found to be more cost-effective than **infliximab** and standard care for **luminal CD** when used as a 1-year **maintenance treatment** with or without induction **therapy** ...